Regeneron Pharmaceuticals Inc (REGN)vsRoyalty Pharma Plc (RPRX)
REGN
Regeneron Pharmaceuticals Inc
$732.87
-0.62%
HEALTHCARE · Cap: $80.02B
RPRX
Royalty Pharma Plc
$45.36
-0.37%
HEALTHCARE · Cap: $26.53B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 503% more annual revenue ($14.34B vs $2.38B). RPRX leads profitability with a 32.4% profit margin vs 31.4%. RPRX appears more attractively valued with a PEG of 1.39. RPRX earns a higher WallStSmart Score of 61/100 (C+).
REGN
Buy58
out of 100
Grade: C
RPRX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-161.4%
Fair Value
$282.06
Current Price
$732.87
$450.81 premium
Margin of Safety
-17.3%
Fair Value
$37.74
Current Price
$45.36
$7.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 57.7%
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Moderate valuation
4.8% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin. Profitability is solid with margins at 32.4% and operating margin at 57.7%. PEG of 1.39 suggests the stock is reasonably priced for its growth.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
RPRX is growing revenue faster at 4.8% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RPRX scores higher overall (61/100 vs 58/100), backed by strong 32.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?